Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

<< Previous

Bullboard Posts

Next >>

Post by threefiftynineon Jun 09, 2020 8:26am

124 Views

Post# 31127734

----2 WEEKS IN TO THE PP---NEWS IMMINENT---

FROM MPARTNERS---- Jordan Puritt Thu, May 28, 9:26 AM (12 days ago) to me Hi ******** Yes, that is the goal. There is ongoing work on the pre clinical trials for covid as well as oncology. COVID is a focal point though and obviously topical. Therefore as the work progresses there should be ongoing news to support the stock. benefit of PP is the 3 year warrant.

<< Previous

Bullboard Posts

Next >>

Record Q3: Equinox Gold achieves commercial production at Greenstone Mine